moneyheap
ABCL · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is AbCellera Biologics Inc. Common Shares (ABCL) stock moving?
AbCellera reported Q3 2026 results on Nov 9 with sales of $10.639M against an $8.416M estimate, and a loss of $(0.13) per share against $(0.16) expected. The shares rose 5.2% that day to $12.50 on heavy volume of about 3.0M, and held near $12.46 on Nov 10 with volume of about 3.9M. Stifel kept its Buy rating and raised its target from $9 to $14, and Jefferies initiated at Buy with a $21 target on Oct 30. Both targets sit above the current price, which supports the bullish case. The stock has traded between $10.76 and $13.86 over the last 30 days, and the Nov 5 low of $10.76 followed a sell-off after a strong late-October rally. The company will present at the UBS conference on Nov 17, which is a near-term event to watch. The evidence is solid for analyst sentiment and the earnings beat, but the market data shows the stock still trading in a broad range, and the research base is small.
News behind the analysis
- Stifel Raises Price Target for AbCellera BiologicsStifel raised its price target on AbCellera from $9 to $14. The stock closed at $12.46 on Nov 10.
- Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14Stifel kept its Buy rating and lifted its target to $14 after the quarterly results.
- AbCellera Reports Q3 2026 Business ResultsAbCellera released its Q3 2026 financial and business results, furnished to the SEC in an 8-K on Nov 9.
- AbCellera Biologics Q3 2026 Earnings Call TranscriptThe transcript of the Q3 2026 earnings call, held Nov 9, is now available.
- AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M EstimateQ3 loss per share was $(0.13) against a $(0.16) estimate. Sales of $10.639M beat the $8.416M estimate by about 26%.
- AbCellera to Present at the UBS Global Biopharma ConferenceAbCellera will take part in the UBS Global Biopharma Conference on Nov 17, 2026.
- Jefferies & Co. Initiates Coverage on AbCellera Biologics with Buy RatingJefferies initiated coverage with a Buy rating and a $21 price target. The stock closed at $12.27 that day.
About AbCellera Biologics Inc. Common Shares
AbCellera is a clinical-stage biotech company based in Vancouver that uses its AI-assisted antibody discovery platform to find and develop antibody medicines. It started out mainly as a discovery partner for other drugmakers. It is now moving its own drugs into the clinic, led by ABCL635, a non-hormonal antibody for menopausal hot flashes that reported positive Phase 2 results in August 2026, and ABCL575, which is in Phase 1.
How it makes money
Revenue is currently small, roughly $4 million in Q2 2026, and the company runs at a loss. Most of its income comes from research fees, upfront payments and milestone payments from partners who use its platform to discover antibodies. It also holds rights to possible future royalties on partner drugs: about 35 partner-led programs, 12 of them in clinical trials, as of mid-2026. Long term, the company aims to earn money from its own drugs if they are approved. It earned large COVID-19 antibody royalties in 2020–2022, but those have mostly ended. It funds its operations from a cash and securities balance of roughly $565 million (mid-2026), which a public offering has since added to.
What usually moves ABCL
- ABCL635 clinical data and Phase 3 plans
- ABCL575 Phase 1 readout and pipeline progress
- New partnership deals and milestone payments
- Cash burn and share dilution from offerings
- Biotech sector sentiment and interest rates